Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
HIV
COVID-19: In Amb. Birx, the White House gets a scientist, physician, public health expert and global health realist as response coordinator
If the criteria for the selection announced Wednesday night of Vice President Mike Pence to lead the U.S. efforts to contain the spread of COVID-19 seemed […]
Tuberculosis
Mass TB screening with point-of-care test is cost-effective, Brazil prison study shows
Suppose you have a large group of people, confined together, considered likely to pose a threat to people outside their walls, but without the ready means […]
Research & Development
In a decade of global health advances, Science Speaks coverage finds movement toward equity
This year marks the close of a dynamic decade in global infectious disease research and responses that changed expectations of what humanity can accomplish toward making […]
Policy
Covid-19: As State Department recommends travelers “reconsider” Asia cruise ship travel, CDC separate case count of “repatriated”
Moves come as WHO DG Tedros warns amid sluggish international funding response that “the window of opportunity” to control coronavirus spread is “narrowing” Reflecting rising concerns […]
Pingback: Race, Sex, and Clinical Outcomes in Early HIV Infection | Liver cancer Blog
Pingback: World TB experts convene, work to blaze the trail to slow disease spread | Science Speaks: HIV & TB News